FDA Approved: DUPIXENT — Supplemental Application (sanofi-aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for DUPIXENT (dupilumab) submitted by Sanofi-Aventis U.S. LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Atopic Dermatitis
• Eosinophilic Esophagitis
• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

SUPPL AP for DUPIXENT (DUPILUMAB)